SNO Annual Report 2022v2

SOCIETY FOR NEURO-ONCOLOGY Annual Report 2022

soc-neuro-onc.org

This Annual Report covers the SNO 2022 fiscal year, from July 1, 2021 through June 31, 2022.

soc-neuro-onc.org

From the President Tracy Batchelor

Dear Colleagues,

We had a successful in person annual meeting in Tampa this year. We received a record number of scientific abstract submissions, and we had a record number of meeting attendees. And, for the first time in SNO history, we have surpassed 3,000 society members. We celebrate that the majority of our elected SNO leaders are now women and that all 5 officers elected to the SNO Board of Directors this year were women. To further advance the principles of diversity, equity, and inclusion SNO has engaged a consultant to work with the leadership to develop a strategic plan for our society. We will incorporate these principles into the fabric of all SNO programs and activities. In closing, I would like to acknowledge the dedication of our members who are on the frontlines of clinical care, teaching, and research. It is thanks to their volunteerism, resilience, creativity, and collaborative spirit that I am confident SNO will continue to flourish well into the future.

Despite the lingering effects of the pandemic, I am pleased to share with you that the state of our Society is strong. I thank my predecessor, Gelareh Zadeh, who ably guided SNO during her term as President under challenging circumstances. I also thank the SNO Executive Committee –Vice President Daphne Haas-Kogan, Secretary Treasurer Jill Barnholtz-Sloane, and Executive Director Chas Haynes – as well as the SNO board of directors, journal editors, committee chairs, and track leaders, who collectively provided outstanding leadership in advancing our mission. And a special word of thanks to the SNO administrative staff for their remarkable dedication and tireless efforts on behalf of our members. We launched several important new initiatives this year. The new, weekly SNO Digest provides timely and important information on SNO activities to over 18,000 members and other neuro-oncology colleagues in 52 different countries. In recognition of the fact that most brain tumor patients receive their care in the community, a new Community Neuro- Oncology Committee was established to foster collaborative relationships with community providers of neuro-oncology care. In keeping with our efforts to invest in the next generation of neuro-oncology professionals, a new Career Development and Training Committee was launched to provide resources, support, and mentorship to students, residents, fellows, and mid-career members.

Sincerely,

2 Society for Neuro-Oncology

soc-neuro-onc.org

Our Mission

The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care.

- 2022 Society for Neuro-Oncology Annual Meeting

From the Executive Director Chas Haynes

I am so proud of the members of the SNO administrative team, who -- in the face of unique adversity and uncertainty -- have remained mission- focused and dedicated to delivering outstanding education, resources and new initiatives to our multidisciplinary stakeholders. The shared experiences and learnings of the pandemic have in many ways made the Society stronger and more dynamic, especially in terms of the delivery of electronic education. And, as we return to in-person meetings, we are now able to incorporate this knowledge into our core educational offerings. I am immensely grateful to immediate past SNO President, Gelareh Zadeh, and current President, Tracy Batchelor, for their skillful diplomacy and leadership during these difficult times. Thanks to their efforts, SNO remains uniquely positioned to support our international membership as we build community, increase diversity, and generate data- driven education and innovation.

Dear Society Members and Friends of SNO,

As you will read in the pages that follow, SNO continues its remarkable trajectory of growth and remains committed to adding value to its members in North America and around the world.

Sincerely,

Society for Neuro-Oncology 3

soc-neuro-onc.org

The Neuro-Oncology Family of Journals

The Neuro-Oncology family of journals continues to provide exceptional value to the field.

SNO’s flagship journal, Neuro-Oncology is committed to publishing the highest quality research to enhance the scientific understanding of CNS tumors. Published in partnership with the European Association of Neuro- Oncology, Neuro-Oncology Practice continues to perform well, and is an important educational resource for those on the frontlines of clinical care. Also published in partnership with EANO, Neuro-Oncology Advances is the premier Open Access title in the field and ensures that SNO is at the forefront of academic publishing. The Society for Neuro-Oncology is pleased to share that the most recent Journal Citation Reports™ provides that the Impact Factor for Neuro-Oncology , has risen to 13.029 (up from 12.30).

Given the relatively narrow editorial focus of Neuro- Oncology as a subspecialty publication, these are remarkable statistics, and the Society is grateful to Kenneth Aldape who served as Editor-in-Chief of Neuro-Oncology during the period that the new citation report covers.

Citation Impact – A Quality Metric

13.029

12.3

10.091 10.247

9.384

2017

2018

2019

2020

2021

New Editorial Leadership for Neuro-Oncology This year SNO announced the appointment of Susan Chang as the new Editor-in-Chief of Neuro-Oncology. Dr. Chang succeeds Dr. Kenneth Aldape. Dr. Chang is a Professor of Neurological Surgery at the University of California, San Francisco Weill Institute for Neurosciences, and co-leader of the Neuro-Oncology Program at the Helen Diller Family Comprehensive Cancer Center. No stranger to editorial leadership, she formerly served as the Founding Editor-in-Chief of Neuro-Oncology ’s sister title, Neuro-Oncology Practice . Her outstanding record of academic excellence, past service to the Society, and familiarity with the neuro-oncology publishing enterprise, makes her the ideal candidate to advance the educational mission of the journal. Commenting on her appointment, Dr. Chang said: “I am humbled and honored to be named to this role. I stand on the shoulders of giants – former Editors Drs. Darell Bigner, W.K. Alfred Yung, Patrick Wen, and Kenneth Aldape – and I am eager to build on their outstanding efforts to take the journal to new heights. I look forward to working with the leaders of ASNO, EANO and SNO, the Editorial Board, and all neuro-oncology stakeholders, as we build community, increase diversity, and generate data-driven education and innovation to our readers around the world.”

4 Society for Neuro-Oncology

soc-neuro-onc.org

Neuro-Oncology is currently ranked 8 th out of all 212 in Clinical Neurology titles and 21 st out of all 245 Oncology titles.

Neuro-Oncology Editor-in-Chief Susan Chang Neuro-Oncology Practice Editor-in-Chief Martin Taphoorn Neuro-Oncology Advances

Editor-in-Chief Gelareh Zadeh

Society for Neuro-Oncology 5

soc-neuro-onc.org

New Initatives

Improving Diversity, Equity & Inclusion DEI is imperative for SNO. It is not only the right thing to do, but the smart thing to do – for our field, and for our patients. SNO has recently engaged a consultant to help the Society craft a longitudinal plan for incorporating the principles of DEI into all our programs and events.

Engaging the Community Practitioner

We recognize that most brain tumor patients are seen in the community setting. This year, SNO embarked on a new initiative dedicated to ensuring patients obtain the best possible treatment wherever they receive their care.

Expanding E-Learning Opportunities Officially launched in April, the Neuro-Oncology Academy contains over 60 unique presentations in 14 modules covering all neuro-oncology subspecialties.

More Education on Pediatric Neuro-Oncology

SNO continues to support and invest in pediatric education. A Pediatric Tumor Board has been launched, and planning is already underway for the 2023 Pediatric Neuro-Oncology Research Conference. SNO also provided administrative support for the 2022 International Symposium on Pediatric Neuro-Oncology event in Hamburg.

6 Society for Neuro-Oncology

soc-neuro-onc.org

Improving Member Communications

This year SNO launched the SNO Digest. In this weekly e-newsletter, we aim to provide the latest news related to the neuro-oncology field by highlighting publications from the Neuro-Oncology family of journals, key clinical trials, podcast features, information on upcoming meetings and SNO seminars, updates from the SNO committees, featured job openings and opportunities for

advocacy. This Digest also seeks to become a staple resource of information that brings together our affiliated fields and societies. In addition, special “meeting editions” of the SNO Digest will be published twice per-day during the course of the Annual Meeting.

Investing the Future New initiatives were launched this year to attract the best and the brightest young professionals to our field, and to provide the resources, mentorship and support throughout the trajectory of our members’ careers.

Working with Sister Societies SNO was proud to partner with the American Society of Clinical Oncology (ASCO) on the Conference on CNS Clinical Trials and Brain Metastases held August 12-13, 2022, in Toronto, Canada. Also during this fiscal year, SNO co- published practice guidelines with ASCO, the American Society for Radiation Oncology, and the European Association of Neuro-Oncology.

Global Education The Society for Neuro-Oncology in Sub-

Saharan Africa (SNOSSA) held its 2022 Annual Conference July 22-24, 2022, in Accra, Ghana. SNO looks forward to collaborating with the leadership of SNOSSA on future events. After a hiatus due to COVID, international outreach travel scholarships for the SNO Annual Meeting were reintroduced for the 2022 Annual Meeting.

Society for Neuro-Oncology 7

soc-neuro-onc.org

2021 Annual Meeting Boston, Massachusetts

Chairs

Women in Neuro-Oncology Awards

CNS Rare Disease Award Yohei Miyake

Scientific Chairs Albert Kim Priscilla Brastianos Farshad Nassiri

WiN Mentorship Award Amy Heimberger

CNS Rare Disease Award Marta Penas-Prado

WiN Mid-Career Exemplary Physician Award Priscilla Brastianos WiN Basic/Translational Science Research Award Defne Bayik

CNS Metastases Award Philipp Karschnia

Education Day I – Biomarkers Daniel Orringer Houtan Noushmehr Susan Short

CNS Metastases Award Christopher Alvarez-Breckenridge

Education Day II - Multidisciplinary Practice

Neuroimaging Award Anahita Fathi Kazerooni

Maureen Daniels Sandra Johnston

WiN Clinical Research Award Emma Nicklin

Pathology Award Frederick S. Varn

Awards

Abstract Awards

Pediatric Basic Science Award Yuan Pan

Lifetime Achievement Award Eric Bouffet

Basic Science Award David D. Tran

Mary Marit Swenson Award for Pediatric DMG/DIPG Robert Siddaway

Victor Levin Award & Lecture Timothy Cloughesy

Basic Science Award Dena Panovska

Abhijit Guha Award & Lecture Amy Heimberger (presented at the AANS/CNS Section on Tumors Conference) Jan Esenwein Public Service Award Nicole Willmarth

Basic Science Award Varun Venkataramani

Radiation Award Roman O. Kowalchuk, MD

Clinical Trials Award Patrick Y. Wen

Survivorship Award Heather Leeper

Clinical Trials E. Antonio Chiocca

Surgery Award Clark C. Chen

Clinical Trials John H. Sampson

Andrew Parsa Young Investigator Award Gilles Berger

2021 Annual Meeting

Abstracts 913

Unique Countries 30

Attendees (in-person) 1640

Exhibitors 45

8 Society for Neuro-Oncology

soc-neuro-onc.org

2022 Annual Meeting Tampa Bay, Florida

Chairs

Women in Neuro-Oncology Awards

CNS Rare Disease/Neurogenetic Tumor Syndromes Award Scott R. Plotkin

Scientific Chairs Priscilla Brastianos Shawn Hervey-Jumper Albert H. Kim

WiN Mentorship Award Ute Bartels

Healthcare Equity Award Joshua A. Budhu

WiN Mid-Career Exemplary Physician Award Lakshmi Nayak WiN Basic/Translational Science Research Award Zulekha A. Qadeer

Track Leader Farshad Nassiri

Neuro-Imaging Award Maciej Harat

Education Day I – Cancer Neuroscience Michelle Monje Humsa Venkatesh Varun Venkataramani

Pathology Award Simona Migliozzi

Radiation Award Justin Wang

WiN Clinical Research Award Anahita Fathi Kazerooni

Education Day II – CNS Cancer Survivorship Milan Chheda Mariella Filbin Jennie Taylor Jeffrey Wefel

Marit Mary Swenson Award for Pediatric DMG/DIPG Charles A. Day

Abstract Awards

Basic Science Award Takahide Nejo

Pediatric Basic Science Award Karen D. Wright

Basic Science Award Giuliana V. Zarrella

Awards

Surgery Award Philipp Karschnia

Lifetime Achievement Award Stuart A. Grossman

Basic Science Award Martha A. Cady

Survivorship Award Kelcie D. Willis

Victor Levin Award & Lecture Michelle Monje

Clinical Trials Award David Peereboom David Reardon

Andrew Parsa Young Investigator Award Julie Bennett

2022 At Glance The Annual Meeting enjoyed robust participation, from both North American and Internationally. Jan Esenwein Public Service Award Adam Hayden Clinical Trials Award Capucine Baldini CNS Metastases Award Lu Sun Abhijit Guha Award & Lecture Manish K. Aghi

2022 Annual Meeting

Abstracts 1153

Unique Countries 48

Attendees (in-person) 2570

Exhibitors 57

Society for Neuro-Oncology 9

soc-neuro-onc.org

Support and Gifts

2021 and 2022 Annual Meetings

Supporters

AstraZeneca Azurity Pharmaceuticals Bayer Biocept Brain Tumor Network Brainlab BTG Specialty Candel Therapeutics/ Advantagene Inc. Caris Life Science

Seagen Siteman Cancer Center SonALAsense Stemline, A Menarini Group Company

Platinum Level American Brain Tumor Association AstraZeneca Chimerix National Brain Tumor Society Novocure The Sontag Foundation

The Brain Tumor Charity The Sontag Foundation University of Florida Neuroscience Varian Zap Surgical

Benefactor Level Bristol-Myers Squibb Kazia Therapeutics Orbus Therapeutics

CERN Foundation at NBTS Children’s Tumor Foundation Chimerix ClearPoint Neuro, Inc. Cortech.ai Day One Biopharmaceutical Designs for Vision, Inc. Elekta End Brain Cancer Intiative FieldCure GT Medical Technologies Head For The Cure Foundation Illumina, Inc. Imaging Biometrics International Brain Tumor Alliance Ivy Brain Tumor Center Kiyatec, Inc.

2021 SNO Pediatric Conference

Supporters

Supporter Level Bayer Day One Biopharmaceutical DNATrix Illumina, Inc. Seagen SonALAsense Contributor Level 10X Genomics Beigene Denovo Biotherapeutics Eisai EndBrainCancer Intitative Monteris Medical Nationwide Children’s Hospital Northwest Biotherapeutics Plus Therapeutics Pyramid Bioscience SDP Oncology

Presenting Supporter Pediatric Brain Tumor Foundation

Platinum Level Supporters American Brain Tumor Association Bayer National Brain Tumor Society The Sontag Foundation

Silver Level Supporter AstraZeneca Chimerix, Inc. Orbus Therapeutics

Medidata Medtronic Merck Mirati Therapeutics

2021 ASCO/SNO Conference on Clinical Trials

Moffitt Cancer Center Monteris Medical, Inc. National Brain Tumor Society National Cancer Institute NICO Corporation Northwest Biotherapeutics Novocure Orbus Therapeutics, Inc. Plus Therapeutics Pyramid Bioscience Renishaw Neuro Solutions Limited

Grant Support Novocure

2021 Conference on Brain Metastases

General Level Supporter Azurity Pharmaceuticals

Supporters

Exhibitors 10x Genomics Accuray Alexion Pharmaceuticals American Brain Tumor Association

Platinum Level Supporters American Brain Tumor Association Chimerix, Inc. National Brain Tumor Society

Reveal Surgical Rosman Search

15 Society for Neuro-Oncology 10 Society for Neuro-Oncology

soc-neuro-onc.org

Novocure Seagen The Sontag Foundation Silver Level Supporters Illumina Orbus Therapeutics Bronze Level Supporters Kazia Therapeutics Monteris Medical

GT Medical Technologies Illumina, Inc. Kazia Therapeutics Monteris Medical, Inc. National Brain Tumor Society Novocure Medical Affairs Orbus Therapeutics, Inc. Seagen The Sontag Innovation Fund and the Brain Tumor Network Varian Zap Surgical

Ali K Choucair in Memory of Ab Guha

Victor Levin for the Victor Levin Founders Fund

AmazonSmile Foundation

2022 Clinical Trials and Brain Metastases Conferences

Maximal Safe Brain Tumor Resection Conference

Supporters

Supporters

Platinum Level Supporters American Brain Tumor Association Bristol-Myers Squibb National Brain Tumor Society The Sontag Innovation Fund and the Brain Tumor Network

Platinum Level Supporters NX Development Corporation Omniscient Stryker Bronze Level Supporters GT Medical Technologies Focused Ultrasound Foundation Hemerion

Gold Level Supporter Novocure Medical Affairs

Silver Level Supporters Daiichi Sankyo Orbus Therapeutics Bronze Level Supporters Illumina Kazia Therapeutics

Gifts

The Blackbaud Giving Fund on Behalf of Price Waterhouse Coopers LLP and its Donors

Monteris Medical Plus Therapeutics Seagen Varian

YourCause on Behalf of Bosch and its Donors

Exhibitors American Brain Tumor Association Biocept Bristol-Myers Squibb Daiichi Sankyo

Childhood Brain Tumor Foundation for International Outreach

Society for Neuro-Oncology 11

soc-neuro-onc.org

Financial Highlights Fiscal Year Ended June 30, 2021

The following financial highlights are prepared by management of the Society for Neuro- Oncology for the fiscal year ended June 30, 2021 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.soc-neuro-onc.org.

Statement of Financial Position highlights, as of June 30, 2021:

Cash and cash equivalents

$ 2,302,000

Investments

$ 3,678,000

Contributions receivable

$ 509,000

Endowment assets

$ 418,000

Total assets

$ 6,907,000

Liabilities

$ 298,000

Net assets

$ 6,609,000

Total liabilities & net assets

$ 6,907,000

Statement of Activities highlights, for the fiscal year ended June 30, 2021:

Total revenues and other support

$ 3,912,000

Total program and supporting service expenses

$ 2,154,000

Change in net assets

$ 1,758,000

12 Society for Neuro-Oncology

soc-neuro-onc.org

Financial Highlights Fiscal Year Ended June 30, 2022

The following financial highlights are prepared by management of the Society for NeuroOncology for the fiscal year ended June 30, 2022 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.soc-neuro-onc.org.

Statement of Financial Position highlights, as of June 30, 2022:

Cash and cash equivalents

$ 2,091,000

Investments

$ 3,121,000

Contributions receivable

$ 895,000

Endowment assets

$ 317,000

Total assets

$ 6,424,000

Liabilities

$ 305,000

Net assets

$ 6,119,000

Total liabilities & net assets

$ 6,424,000

Statement of Activities highlights, for the fiscal year ended June 30, 2022:

T otal revenues and other support

$ 3,869,000

Total program and supporting service expenses

$ 4,359,000

Change in net assets

$ (490,000)

Society for Neuro-Oncology 13

soc-neuro-onc.org

2022 Leadership

Guidelines Manmeet Ahluwalia, Maryam Fouladi, Tobias Walbert Membership Omar Arnaout, Oluwatosin Akintola, Julie Miller, Alissa Thomas

Officers

Basic Science Representative Joseph Costello

President Tracy Batchelor

Radiation Oncology Representative Jennifer Yu

Vice President Daphne Haas-Kogan

Foundation Board

Secretary-Treasurer Jill Barnholtz-Sloan

Public Policy Antonio Chiocca, Erik Sulman

Mitchel S. Berger, Susan Chang Antonio Chiocca, Victor A. Levin David Reardon

Executive Director (Ex Officio) Chas Haynes

Training & Career Development Jaishri Blakeley, Ashley Margol, Vinay Puduvalli, Shaan Raza Wellness Alvina Acquaye, Katy Peters, Shlomit Yust-Katz

Journal Editors-in-Chief

Board of Directors

Neuro-Oncology Susan Chang

Immediate Past President Gelareh Zadeh

Neuro-Oncology Practice Martin Taphoorn

Journal Editor-in-Chief (Ex Officio) Susan Chang

Women and Diversity Macarena de la Fuente, Jose McFaline Figueroa, Reena Thomas

Neuro-Oncology Advances Gelareh Zadeh

Allied Health Representative Susan Bell

Committee Chairs

Young Investigators Tab Cooney, Elizabeth Gerstner, Sam McBrayer

Neurology Representative Eudocia Q. Lee

Audit James Perry

Young Investigator Representative Gavin Dunn

Conference Chairs

Awards Priscilla Brastianos, Eva Galanis, Shawn Hervey-Jumper, Albert Kim, Gelareh Zadeh

Annual Meeting Priscilla Brastianos, Albert Kim, Shawn Hervey-Jumper

Neurosurgery Representative Linda Bi

Bylaws Nick Butowski

Radiology Representative Benjamin Ellingson

Annual Meeting, Track Leader Farshad Nassiri

Communications Iyad Alnahhas, Linda Bi, Nicholas Gonzalez-Castro Community Neuro-Oncology Sajeel Chowdhary, Christine Lu-Emerson External Relations John de Groot, Erin Dunbar, Karisa Schreck

Pathology Representative Jason Huse

Annual Meeting, Survivorship Education Day Milan Chheda, Mariella Filbin, Jennie Taylor, Jeffrey Wefel Annual Meeting, Neuroscience Education Day Michelle Monje, Varun Venkataramani, Humsa Venkatesh

Pediatrics Representative Annie Huang

Medical Oncology Representative Erin Dunbar

15 Society for Neuro-Oncology 14 Society for Neuro-Oncology

soc-neuro-onc.org

Staff

Survivorship Heather Leeper, Susan Chang

J. Charles (Chas) Haynes Executive Director Shelley Pressley Director of Administration Ginger Vazquez Manager of Technology Integration Tara A. Mammoser Manager of Medical Education MeLesa Ritterhouse Manager of Neuro-Oncology Academy & CME Caroline K. Noor Manager of Member Services and Giving Kristina Knight Manager of Medical Education Megan Bell-Johnston Exhibits and Support Specialist Gabrielle Griffin Marketing and Communications Specialist

SNO/ASCO Conference on CNS Clinical Trials and Brain Metastases Priscilla Brastianos, Mustafa Khasraw

Track Chairs

Basic Science Joseph Costello, Frank Furnari, Annette Molinaro

Brain Metastases Alexandra Zimmer, Priya Kumthekar

Cancer Neurology Eudocia Lee, Maciej Mrugala

Clinical Trials Solmaz Sahebjam, Mustafa Khasraw

CNS Rare Disease Mark Gilbert, Terri Armstrong

Molecular Pathology Jason Huse, Sandro Santagata, Stephen Yip

Neurogenetic Tumor Syndromes Brigitte Widemann, Jaishri Blakeley

Neuroimaging Derek Johnston, Raymond Huang, Javier Villanueva-Meyer

Amelia Hutsell Administrative Specialist

Neurosurgery Ian Dunn, Isabella Germano, Lissa Baird

Pamela Newell Bookkeeper

Radiation Sciences Debra Yeboa, Jennifer Yu

Pediatrics Annie Huang, Robert Wechsler-Reya

Society for Neuro-Oncology 15

CONTACT US

SOCIETY FOR NEURO-ONCOLOGY PO Box 273296 Houston, TX 77277

tel 713.526.0269 fax 832.201.8129

soc-neuro-onc.org

Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16

Made with FlippingBook - Share PDF online